TRV045

About Trevena

Trevena's mission is to develop safer and more effective CNS therapies by exploiting biased ligand signaling at G protein-coupled receptors (GPCRs). Its primary achievement is the 2020 FDA approval of OLINVYK, a biased mu-opioid receptor agonist for acute pain, though commercial uptake has been limited. The company's current strategy is to advance its early-stage pipeline, including TRV045 for neuropathic pain and epilepsy, while navigating severe financial constraints and seeking strategic alternatives to sustain operations.

About Trevena

Trevena's mission is to develop safer and more effective CNS therapies by exploiting biased ligand signaling at G protein-coupled receptors (GPCRs). Its primary achievement is the 2020 FDA approval of OLINVYK, a biased mu-opioid receptor agonist for acute pain, though commercial uptake has been limited. The company's current strategy is to advance its early-stage pipeline, including TRV045 for neuropathic pain and epilepsy, while navigating severe financial constraints and seeking strategic alternatives to sustain operations.

Therapeutic Areas

Other Diabetic Neuropathic Pain Drugs